Ending diagnostic odysseys and inspiring hope
For patients with rare and complex conditions, physicians and other healthcare professionals need trusted answers. Our tests are developed through leading-edge research and unmatched clinical expertise, creating a diagnostics ecosystem that delivers insights that set a new standard in diagnostic care.
Successful patient outcomes are our priority, and we work with hospitals and physicians around the world to elevate diagnostic excellence everywhere. As part of Mayo Clinic’s healthcare system, we understand the best care is provided locally. We complement local expertise by working with clients and logistics organizations to optimize the specimen journey to our laboratories, enabling physicians to get the results they need and patients to remain at home, focused on healing.
Relentless pursuit of answers
Ongoing research propels test development at Mayo Clinic Laboratories, enabling innovative testing that delivers faster, reliable answers to confidently diagnose patients. Our test results not only equip physicians and patients with meaningful diagnostic, prognostic, and therapeutic insights, they also provide hope for a healthier future.
Experience and expertise you can trust
Mayo Clinic Laboratories’ scientists and physicians are leaders in their fields and able to consult on test selection, utilization, and results interpretation. The exchange of knowledge is a founding principle of Mayo Clinic, and we are committed to sharing lessons we’ve learned with our global collaborators through educational opportunities to help improve care delivery in local practices. This is supported through an expansive library of educational content, podcasts, and stories that showcase breakthroughs in test development and perspectives from Mayo Clinic experts.
Access to groundbreaking diagnostics
Driven by an instinct to innovate, we transform scientific discoveries into meaningful advancements in diagnostic testing. Supported by a robust network of Mayo Clinic physicians and scientists and forward-thinking laboratory partners, we foster access to new and advanced testing, much of which is unavailable elsewhere. This integration connects physicians and hospitals around the world with multiple innovative solutions all in one place to support better patient outcomes.
“We treat all of the specimens we receive with the same high degree of care and quality, regardless of where the sample is coming from. We could be testing a sample from a patient that lives in Rochester, Minnesota, or from someone that lives halfway across the world.”
Bobbi Pritt, M.D., Director of the Clinical Parasitology Laboratory
OUR DIFFERENCE
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.
Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Justin Juskewitch, M.D., Ph.D., and Andrew Norgan, M.D., Ph.D., both assistant professors of laboratory medicine and pathology at Mayo Clinic, to talk about informatics for the pathologist.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers relevant to pediatric presentations of the diseases.
Loralie Langman, Ph.D., explains the difference between chain of custody and clinical toxicology testing. Chain of custody is a process used for toxicology testing when the results might have legal implications for the individual tested. Clinical toxicology testing is used for routine medical care. Mayo Clinic Laboratories offers a full range of clinical and forensic toxicology testing.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Matt Binnicker, Ph.D., director of Clinical Virology and vice chair of practice in the Department of Laboratory Medicine and Pathology at Mayo Clinic, to discuss the laboratory medicine perspective of Monkeypox.
This list includes updates posted to mayocliniclabs.com during the month of September.
Lisa Brown, quality specialist for Mayo Clinic Laboratories customer service, explains working "behind the scenes" when a client calls Mayo Clinic Laboratories with an inquiry, that call is typically picked up within 20 seconds by an agent from Mayo Laboratory Inquiry (MLI). There are no phone trees or automated menus to wade through before they reach an agent. Agents mind the phones 24/7, 365 days a year.
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
By collaborating with Mayo Clinic Laboratories, Morris Hospital & Healthcare Center has been able to expand complex and specialized lab testing in the communities they serve.
In Mayo Clinic’s Advanced Diagnostics Laboratory, there are dozens of projects underway at once to develop new technologies, discover novel findings, validate new tests, and support physicians in providing advanced patient care. For example, researchers are using phage immunoprecipitation sequencing (PhIP-Seq) to discover new serological biomarkers for autoimmune diseases. In a recent study using PhIP-Seq, Mayo Clinic researchers discovered a previously unknown antibody marker for immune-mediated rippling muscle disease (iRMD). This finding will support testing options and accurate diagnosis of iRMD, helping physicians treat patients with iRMD and restore their quality of life.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.